This downward trend was observed to be directly opposite to PSP-treated cells with no inhibitory conditions from Figure 4E. However, a significant increase in total PKR was seen for every group present with the highest fold difference of 8.77 for PSP treatment before viral infection (Figure 5F). This evidence concerns the gene EIF2AK2 and viral infectious disease.